Developer docs
API playgroundTry for free, no card

Search company profiles

Ampharco

Full company profile

uuid0024qv5

Namestring
Ampharco
Legal namestring
Công ty Cổ phần Dược phẩm Ampharco U.S.A
Websiteurl
ampharcousa.com
Company typeenum
Private
Founded yearint
1969
Descriptiontext

Ampharco U.S.A (Công ty Cổ phần Dược phẩm Ampharco U.S.A) is a privately held Vietnamese pharmaceutical manufacturer and distributor founded in 1969 as Thai Van Labs and operating from Nhon Trach 3 Industrial Park, Dong Nai, with a branch in Ho Chi Minh City. The company operates two manufacturing plants: Factory A, which has held WHO-GMP certification since 2005, and Factory B, which received EU-GMP certification in March 2025, together producing approximately one billion galenic units per year across tablets, film-coated and controlled-release tablets, soft capsules, powders, liquids, and topical dosage forms. Its portfolio spans 15 therapeutic categories including cardiovascular, respiratory, antibiotics, anti-inflammatory, neurology-musculoskeletal, urology-reproductive health, topical products, endocrine, infusion, and health supplements, organized under house brands such as AMFAGOLD, SOS, MAXX, NIDAL, and VICRAAPC.

The company generates revenue through three streams: proprietary pharmaceutical manufacturing and sales to Vietnamese pharmacies, wholesalers, and hospitals; contract manufacturing under OEM and technology-transfer agreements, most notably a 2025 deal with France's Servier covering roughly half of Servier's Vietnam-distributed volume across five medicines for diabetes, cardiovascular disease, and venous insufficiency, and an ongoing Sanofi OEM relationship dating to 2012 covering 120+ transferred SKUs; and GSP-certified warehousing services offered to third parties. Distribution is nationwide across all provinces of Vietnam through a mix of direct pharmacy supply, wholesale (including with DKSH), hospital tenders, and field-marketing to healthcare professionals, supported by over 10,000m² of GSP-certified warehousing in Dong Nai and the HCMC branch. The company employs 300+ staff and positions itself as a long-tenured, GMP-compliant partner for both Vietnamese healthcare access and multinational technology transfer into Vietnam.

Short descriptiontext

Ampharco U.S.A is a privately held Vietnamese pharmaceutical manufacturer with over 50 years of history, operating WHO-GMP and EU-GMP certified plants producing roughly one billion galenic units yearly across 15 therapeutic categories and distributing nationwide to pharmacies, wholesalers, and hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHo Chi Minh City, Vietnam
HQ citystring
Ho Chi Minh City
HQ countrystring
Vietnam
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines production, health supplements, contract pharmaceutical manufacturing, GSP-certified warehousing
Industry3 codes
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIACAD
Pharmaceutical & Life Sciences Warehousing (GDP-Compliant)
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Warehousing Operations & Contract Storage (Dedicated/Shared)
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Manufacturing and Sales
TypeHardware Sales
Description

Manufacturing and distribution of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, and health supplements. Products sold through pharmacies and hospital tenders across Vietnam.

ampharcousa.com
2Contract Manufacturing (Technology Transfer)
TypeProfessional Services
Description

Technology transfer manufacturing agreement with Servier (France) for production of original brand medicines at EU-GMP certified facility. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam.

ampharcousa.com
3Warehousing Services
TypeManaged Services
Description

GSP-certified warehouse leasing services for pharmaceutical storage, offering both normal and cold condition storage (2-8°C) with capacity over 10,000m².

ampharcousa.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1AMFAGOLD
Description

Health supplements product line including AMFAGOLD 3B, AMFAGOLD 4FLEX, AMFAGOLD ACTIVE JOINT, AMFAGOLD C 1000, AMFAGOLD CORDY PLUS, AMFAGOLD DERMA, AMFAGOLD E-NATURAL, AMFAGOLD G2 PLUS, AMFAGOLD GINKGO, AMFAGOLD HEPA

ampharcousa.com
+7 more records
Core offering1 text field

Ampharco U.S.A manufactures and distributes a comprehensive portfolio of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, antivirals, neurology-musculoskeletal, urology, digestive, endocrine, infusion, antiallergics, topical, bone-joint, and health supplements. The company operates two GMP-certified manufacturing plants in Vietnam (WHO-GMP Factory A since 2005 and EU-GMP Factory B since March 2025) with over 1 billion galenic units annual capacity, and provides GSP-certified warehousing services across a nationwide distribution network.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ampharco U.S.A Pharmaceutical Joint Stock Company operates as a diversified pharmaceutical manufacturer with over 50 years of experience. The company produces a comprehensive portfolio spanning 15 product groups including: Antiallergics, Antibiotics, Anti-inflammatory-Analgesics-Antipyretics, Antivirals, Bone and Joint, Cardiovascular, Digestive System, Endocrine, Infusion, Neurology-Musculoskeletal, Respiratory, Topical Products, Urology-Reproductive Health, Cosmetics, and Health Supplements. Key product lines include AMFAGOLD health supplements (3B, 4FLEX, ACTIVE JOINT, C 1000, CORDY PLUS, DERMA, E-NATURAL, G2 PLUS, GINKGO, HEPA), MAXXNEURO neurology products, MAXXVITON piracetam products, VICRAAPC sildenafil products, SOSCough herbal products, and various cardiovascular, antibiotic, and infusion medications. The company operates WHO-GMP and EU-GMP certified manufacturing facilities with a GSP-certified warehousing system.

Product and service11 records
1AMFAGOLD Health Supplements
CategoryHealth Supplements
Description

Comprehensive health supplement line covering vitamins, joint care, liver support, skin nourishment, and cerebral circulation. Sold through pharmacies and wholesalers nationwide in Vietnam.

2SOS OTC Pharmaceutical Line
CategoryOTC Pharmaceuticals
Description

Over-the-counter pharmaceutical products covering topical, respiratory, antipyretic, antiallergic, and other self-care conditions. Includes the top-selling SOSLac G3 topical brand. Sold through pharmacies and retail distribution.

3MAXX Specialty Pharmaceutical Line
CategoryPrescription Pharmaceuticals - Neurology & Specialty
Description

Specialty prescription pharmaceutical line covering neurology (Pregabalin, Piracetam, Donepezil, Levetiracetam, Mirtazapine, Gabapentin), musculoskeletal (Baclofen), and other therapeutic areas. Distributed to hospitals via tenders and through pharmacy channels.

4VICRAAPC Erectile Dysfunction Treatment
CategoryPrescription Pharmaceuticals - Urology
Description

Sildenafil 50mg and 100mg film-coated tablets for the treatment of erectile dysfunction in adult males. Sold via pharmacy distribution in Vietnam.

5NIDAL Anti-Inflammatory Analgesics
CategoryPrescription Pharmaceuticals - Anti-Inflammatory
Description

Anti-inflammatory and analgesic pharmaceutical products in multiple formulations including NIDAL PLUS, NIDAL FORT, NIDAL DAY, NIDAL-FLEX 50, and NEO-NIDAL. Distributed through hospital tenders and retail pharmacy channels in Vietnam.

6AMINIC Infusion Solution
CategoryPrescription Pharmaceuticals - Infusion
Description

Amino acid IV infusion solution used for plasma protein reduction and treatment of malnutrition cases. Sold to hospitals via tender processes.

7Cardiovascular Pharmaceutical Products
CategoryPrescription Pharmaceuticals - Cardiovascular
Description

Cardiovascular pharmaceutical products including AmloAPC (hypertension treatment) and ZarelAPC 15 (Rivaroxaban 15mg tablets). Distributed via hospital tenders and pharmacy channels.

8Antibiotic Pharmaceuticals (ZIMAXAPC)
CategoryPrescription Pharmaceuticals - Antibiotics
Description

Antibiotic pharmaceutical products including ZIMAXAPC 500 (Azithromycin 500mg film-coated tablets) for treatment of bacterial infections. Sold via hospital tenders and pharmacy distribution.

9AmphaBio COVID-19 Test Kit
CategoryDiagnostic Test Kits
Description

AmphaBio HT high-throughput PCR COVID-19 diagnostic test kit capable of detecting most known SARS-CoV-2 variants. Licensed by the Vietnam Ministry of Health and supplied to government and healthcare institutions.

10Servier Original Brand Medicine Contract Manufacturing
CategoryContract Manufacturing Services
Description

Contract manufacturing and technology transfer services for Servier (France), producing approximately 50% of Servier's original brand medicines distributed in Vietnam, covering diabetes, cardiovascular, and venous insufficiency treatments at the EU-GMP certified Factory B.

11GSP-Certified Pharmaceutical Warehousing Services
CategoryPharmaceutical Logistics Services
Description

Leasing of over 10,000m² of GSP-certified warehouse facilities for pharmaceutical storage with both ambient and cold-chain (2-8°C) conditions. Located at Nhon Trach 3 Industrial Park, Dong Nai Province, with expansion to five warehouses planned by 2026.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Technology transfer and manufacturing agreement for production of original brand medicines. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam. Servier transferred technology for five key medicines used in treatment of diabetes, cardiovascular diseases, and venous insufficiency. Agreement signed with witnessed by French Consul General and Vietnamese government officials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term partnership for OEM manufacturing. Transferred over 120 SKUs to Sanofi in 2012 (99% of existing drug portfolio at that time). Ongoing OEM manufacturing relationship.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership established as part of globalization goals with leading multinational pharmaceutical companies.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution services partner for pharmaceutical products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Market expansion services company providing distribution and logistics services for pharmaceutical, consumer goods, and other products across Asia. Ampharco's distribution partner; comparable in pharmaceutical supply chain and warehousing capabilities in Vietnam.

TypeDirect peer
Description

One of Vietnam's largest domestic pharmaceutical manufacturers with broad generic portfolio and nationwide distribution. Comparable to Ampharco in therapeutic category breadth, manufacturing scale, and Vietnamese market focus.

TypeBroad incumbent
Description

Global multinational pharmaceutical company and long-standing OEM partner of Ampharco since 2012. Comparable in advanced manufacturing standards and pharmaceutical development, but operates at much larger scale across global markets.

TypeDirect peer
Description

Vietnamese pharmaceutical manufacturer with similar product breadth across multiple therapeutic categories, hospital tender participation, and wholesale distribution across Vietnam.

TypeDirect peer
Description

Leading Vietnamese pharmaceutical manufacturer specializing in branded generic and traditional medicine products. Comparable business model with domestic manufacturing, hospital tender participation, and pharmacy distribution.

6Mekophar
TypeDirect peer
Description

Vietnamese pharmaceutical manufacturer producing branded generics and OTC products across multiple therapeutic categories. Comparable manufacturing, distribution, and Vietnamese market positioning.

7EA Pharma
TypeBroad incumbent
Description

Multinational pharmaceutical company with established partnership with Ampharco, focused on branded pharmaceutical distribution across Asia. Comparable in international pharmaceutical standards and Asian market presence.

TypeBroad incumbent
Description

French multinational pharmaceutical group that signed a 2025 technology transfer agreement with Ampharco for original brand medicine production in Vietnam. Comparable in pharmaceutical manufacturing expertise and cardiometabolic focus, but at significantly larger global scale.

TypeDirect peer
Description

Vietnamese pharmaceutical manufacturer with manufacturing facilities, branded generics, and nationwide distribution. Directly comparable in therapeutic portfolio breadth and Vietnamese market operations.

TypeDirect peer
Description

Vietnamese pharmaceutical company operating manufacturing facilities, distribution, and branded generic products across multiple therapeutic categories. Comparable in scale and domestic market focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ampharco

Pharmaceutical Manufacturingampharcousa.com

Ampharco U.S.A is a privately held Vietnamese pharmaceutical manufacturer with over 50 years of history, operating WHO-GMP and EU-GMP certified plants producing roughly one billion galenic units yearly across 15 therapeutic categories and distributing nationwide to pharmacies, wholesalers, and hospitals.

What Ampharco does

Ampharco U.S.A (Công ty Cổ phần Dược phẩm Ampharco U.S.A) is a privately held Vietnamese pharmaceutical manufacturer and distributor founded in 1969 as Thai Van Labs and operating from Nhon Trach 3 Industrial Park, Dong Nai, with a branch in Ho Chi Minh City. The company operates two manufacturing plants: Factory A, which has held WHO-GMP certification since 2005, and Factory B, which received EU-GMP certification in March 2025, together producing approximately one billion galenic units per year across tablets, film-coated and controlled-release tablets, soft capsules, powders, liquids, and topical dosage forms. Its portfolio spans 15 therapeutic categories including cardiovascular, respiratory, antibiotics, anti-inflammatory, neurology-musculoskeletal, urology-reproductive health, topical products, endocrine, infusion, and health supplements, organized under house brands such as AMFAGOLD, SOS, MAXX, NIDAL, and VICRAAPC.

The company generates revenue through three streams: proprietary pharmaceutical manufacturing and sales to Vietnamese pharmacies, wholesalers, and hospitals; contract manufacturing under OEM and technology-transfer agreements, most notably a 2025 deal with France's Servier covering roughly half of Servier's Vietnam-distributed volume across five medicines for diabetes, cardiovascular disease, and venous insufficiency, and an ongoing Sanofi OEM relationship dating to 2012 covering 120+ transferred SKUs; and GSP-certified warehousing services offered to third parties. Distribution is nationwide across all provinces of Vietnam through a mix of direct pharmacy supply, wholesale (including with DKSH), hospital tenders, and field-marketing to healthcare professionals, supported by over 10,000m² of GSP-certified warehousing in Dong Nai and the HCMC branch. The company employs 300+ staff and positions itself as a long-tenured, GMP-compliant partner for both Vietnamese healthcare access and multinational technology transfer into Vietnam.

Ampharco firmographics

Firmographics
Name
Ampharco
Legal name
Công ty Cổ phần Dược phẩm Ampharco U.S.A
Website
https://ampharcousa.com
Company type
Private
Founded year
1969
Operating status
Operating
Headcount range
51–100 employees
Short description
Ampharco U.S.A is a privately held Vietnamese pharmaceutical manufacturer with over 50 years of history, operating WHO-GMP and EU-GMP certified plants producing roughly one billion galenic units yearly across 15 therapeutic categories and distributing nationwide to pharmacies, wholesalers, and hospitals.
Ownership category
akta.pro rank

Ampharco industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIACAD
Pharmaceutical & Life Sciences Warehousing (GDP-Compliant)
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Warehousing Operations & Contract Storage (Dedicated/Shared)

Keywords

  • Pharmaceutical manufacturing
  • Generic medicines production
  • Health supplements
  • Contract pharmaceutical manufacturing
  • GSP-certified warehousing

Where Ampharco is headquartered

Location

Headquarters

HQ city
Ho Chi Minh City
HQ country
Vietnam
HQ region
Asia

Offices2 records

Markets served

Ampharco business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Manufacturing and Sales: Manufacturing and distribution of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, and health supplements. Products sold through pharmacies and hospital tenders across Vietnam.
  2. Contract Manufacturing (Technology Transfer): Technology transfer manufacturing agreement with Servier (France) for production of original brand medicines at EU-GMP certified facility. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam.
  3. Warehousing Services: GSP-certified warehouse leasing services for pharmaceutical storage, offering both normal and cold condition storage (2-8°C) with capacity over 10,000m².

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Ampharco product offering

Product offering

Core offering

Ampharco U.S.A manufactures and distributes a comprehensive portfolio of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, antivirals, neurology-musculoskeletal, urology, digestive, endocrine, infusion, antiallergics, topical, bone-joint, and health supplements. The company operates two GMP-certified manufacturing plants in Vietnam (WHO-GMP Factory A since 2005 and EU-GMP Factory B since March 2025) with over 1 billion galenic units annual capacity, and provides GSP-certified warehousing services across a nationwide distribution network.

Product overview

Ampharco U.S.A Pharmaceutical Joint Stock Company operates as a diversified pharmaceutical manufacturer with over 50 years of experience. The company produces a comprehensive portfolio spanning 15 product groups including: Antiallergics, Antibiotics, Anti-inflammatory-Analgesics-Antipyretics, Antivirals, Bone and Joint, Cardiovascular, Digestive System, Endocrine, Infusion, Neurology-Musculoskeletal, Respiratory, Topical Products, Urology-Reproductive Health, Cosmetics, and Health Supplements. Key product lines include AMFAGOLD health supplements (3B, 4FLEX, ACTIVE JOINT, C 1000, CORDY PLUS, DERMA, E-NATURAL, G2 PLUS, GINKGO, HEPA), MAXXNEURO neurology products, MAXXVITON piracetam products, VICRAAPC sildenafil products, SOSCough herbal products, and various cardiovascular, antibiotic, and infusion medications. The company operates WHO-GMP and EU-GMP certified manufacturing facilities with a GSP-certified warehousing system.

Differentiator

Problem solved

Functional benefit

Brands

  • AMFAGOLD: Health supplements product line including AMFAGOLD 3B, AMFAGOLD 4FLEX, AMFAGOLD ACTIVE JOINT, AMFAGOLD C 1000, AMFAGOLD CORDY PLUS, AMFAGOLD DERMA, AMFAGOLD E-NATURAL, AMFAGOLD G2 PLUS, AMFAGOLD GINKGO, AMFAGOLD HEPA
  • SOS
  • MAXX
  • NIDAL
  • VICRAAPC
  • USATRYPSIN
  • AMINIC
  • Amphabio

Products and services

  • AMFAGOLD Health Supplements Comprehensive health supplement line covering vitamins, joint care, liver support, skin nourishment, and cerebral circulation. Sold through pharmacies and wholesalers nationwide in Vietnam.
  • SOS OTC Pharmaceutical Line Over-the-counter pharmaceutical products covering topical, respiratory, antipyretic, antiallergic, and other self-care conditions. Includes the top-selling SOSLac G3 topical brand. Sold through pharmacies and retail distribution.
  • MAXX Specialty Pharmaceutical Line Specialty prescription pharmaceutical line covering neurology (Pregabalin, Piracetam, Donepezil, Levetiracetam, Mirtazapine, Gabapentin), musculoskeletal (Baclofen), and other therapeutic areas. Distributed to hospitals via tenders and through pharmacy channels.
  • VICRAAPC Erectile Dysfunction Treatment Sildenafil 50mg and 100mg film-coated tablets for the treatment of erectile dysfunction in adult males. Sold via pharmacy distribution in Vietnam.
  • NIDAL Anti-Inflammatory Analgesics Anti-inflammatory and analgesic pharmaceutical products in multiple formulations including NIDAL PLUS, NIDAL FORT, NIDAL DAY, NIDAL-FLEX 50, and NEO-NIDAL. Distributed through hospital tenders and retail pharmacy channels in Vietnam.
  • AMINIC Infusion Solution Amino acid IV infusion solution used for plasma protein reduction and treatment of malnutrition cases. Sold to hospitals via tender processes.
  • Cardiovascular Pharmaceutical Products Cardiovascular pharmaceutical products including AmloAPC (hypertension treatment) and ZarelAPC 15 (Rivaroxaban 15mg tablets). Distributed via hospital tenders and pharmacy channels.
  • Antibiotic Pharmaceuticals (ZIMAXAPC) Antibiotic pharmaceutical products including ZIMAXAPC 500 (Azithromycin 500mg film-coated tablets) for treatment of bacterial infections. Sold via hospital tenders and pharmacy distribution.
  • AmphaBio COVID-19 Test Kit AmphaBio HT high-throughput PCR COVID-19 diagnostic test kit capable of detecting most known SARS-CoV-2 variants. Licensed by the Vietnam Ministry of Health and supplied to government and healthcare institutions.
  • Servier Original Brand Medicine Contract Manufacturing Contract manufacturing and technology transfer services for Servier (France), producing approximately 50% of Servier's original brand medicines distributed in Vietnam, covering diabetes, cardiovascular, and venous insufficiency treatments at the EU-GMP certified Factory B.
  • GSP-Certified Pharmaceutical Warehousing Services Leasing of over 10,000m² of GSP-certified warehouse facilities for pharmaceutical storage with both ambient and cold-chain (2-8°C) conditions. Located at Nhon Trach 3 Industrial Park, Dong Nai Province, with expansion to five warehouses planned by 2026.

Companies that use Ampharco

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Ampharco technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ampharco partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • Servier (Les Laboratoires Servier)flagshipStrategic or Co-development Partner · 16 April 2025Technology transfer and manufacturing agreement for production of original brand medicines. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam. Servier transferred technology for five key medicines used in treatment of diabetes, cardiovascular diseases, and venous insufficiency. Agreement signed with witnessed by French Consul General and Vietnamese government officials.
  • SanoficoreStrategic or Co-development PartnerLong-term partnership for OEM manufacturing. Transferred over 120 SKUs to Sanofi in 2012 (99% of existing drug portfolio at that time). Ongoing OEM manufacturing relationship.
  • EA PharmaminorStrategic or Co-development PartnerPartnership established as part of globalization goals with leading multinational pharmaceutical companies.
  • DKSH (Distribution Services)minorChannel Partner/ Reseller/ DistributorDistribution services partner for pharmaceutical products.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Ampharco competitors and assessment

Company assessment

Others

  • DKSH: Market expansion services company providing distribution and logistics services for pharmaceutical, consumer goods, and other products across Asia. Ampharco's distribution partner; comparable in pharmaceutical supply chain and warehousing capabilities in Vietnam.

Direct peers

  • DHG Pharmaceutical (Hau Giang Pharma): One of Vietnam's largest domestic pharmaceutical manufacturers with broad generic portfolio and nationwide distribution. Comparable to Ampharco in therapeutic category breadth, manufacturing scale, and Vietnamese market focus.
  • Pymepharco: Vietnamese pharmaceutical manufacturer with similar product breadth across multiple therapeutic categories, hospital tender participation, and wholesale distribution across Vietnam.
  • Traphaco: Leading Vietnamese pharmaceutical manufacturer specializing in branded generic and traditional medicine products. Comparable business model with domestic manufacturing, hospital tender participation, and pharmacy distribution.
  • Mekophar: Vietnamese pharmaceutical manufacturer producing branded generics and OTC products across multiple therapeutic categories. Comparable manufacturing, distribution, and Vietnamese market positioning.
  • Domesco: Vietnamese pharmaceutical manufacturer with manufacturing facilities, branded generics, and nationwide distribution. Directly comparable in therapeutic portfolio breadth and Vietnamese market operations.
  • Imexpharm: Vietnamese pharmaceutical company operating manufacturing facilities, distribution, and branded generic products across multiple therapeutic categories. Comparable in scale and domestic market focus.

Broad incumbents

  • Sanofi: Global multinational pharmaceutical company and long-standing OEM partner of Ampharco since 2012. Comparable in advanced manufacturing standards and pharmaceutical development, but operates at much larger scale across global markets.
  • EA Pharma: Multinational pharmaceutical company with established partnership with Ampharco, focused on branded pharmaceutical distribution across Asia. Comparable in international pharmaceutical standards and Asian market presence.
  • Servier (Les Laboratoires Servier): French multinational pharmaceutical group that signed a 2025 technology transfer agreement with Ampharco for original brand medicine production in Vietnam. Comparable in pharmaceutical manufacturing expertise and cardiometabolic focus, but at significantly larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ampharco compliance and trust

Trust signal

Compliance3 records

Ampharco financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ampharco leadership team

Management profile

Number of profiles

Profiles3 records

Ampharco funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ampharco M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ampharco

What does Ampharco do?

Ampharco U.S.A manufactures and distributes a comprehensive portfolio of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, antivirals, neurology-musculoskeletal, urology, digestive, endocrine, infusion, antiallergics, topical, bone-joint, and health supplements. The company operates two GMP-certified manufacturing plants in Vietnam (WHO-GMP Factory A since 2005 and EU-GMP Factory B since March 2025) with over 1 billion galenic units annual capacity, and provides GSP-certified warehousing services across a nationwide distribution network.

Is Ampharco a public or private company?

Ampharco is a private company. It is classified as unknown and is currently operating.

When was Ampharco founded?

Ampharco was founded in 1969. It employs 51 to 100 people.

Where is Ampharco based?

Ampharco is headquartered in Ho Chi Minh City, Vietnam, in the Asia region.

How does Ampharco make money?

Three revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are contract Manufacturing (Technology Transfer) and warehousing Services.

Who are Ampharco's main competitors?

DKSH is listed as an others. Direct peers are DHG Pharmaceutical (Hau Giang Pharma), Pymepharco, Traphaco, Mekophar, Domesco and Imexpharm. Broad incumbents are Sanofi, EA Pharma and Servier (Les Laboratoires Servier).

Does Ampharco have an API?

No public API is recorded for Ampharco.

What industry is Ampharco in?

Ampharco's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAA, Full-Line Pharmaceutical Wholesalers, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales